(Reuters) -Canada's health regulator has approved Novo Nordisk's diabetes drug, Ozempic, for reducing the risk of kidney ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between ...

Diabetic medicine Ozempic now approved by Health Canada to reduce the risk of further kidney decline among patients with Type ...

Canada's health regulator has approved Novo Nordisk's diabetes drug, Ozempic, for reducing the risk of kidney failure and ...

Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 ...

Health Canada has approved Ozempic for use by Type 2 diabetes patients to reduce the risk of further kidney damage.

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and ...

Health Canada has now approved Ozempic to reduce the risk of kidney decline among patients with type 2 diabetes.

Novo Nordisk announced today that Ozempic® (semaglutide injection) is now approved as the first-and-only medication indicated for both the once-weekly ...

Novo Nordisk (NYSE:NVO) said Tuesday that Health Canada has expanded the label for its diabetes therapy Ozempic, granting approval for use in patients with chronic kidney disease. The new indication ...